Biocytogen to Present Pipeline Assets and R&D Progress at BIO International Convention, June 5-8, 2023
Biocytogen’s antibody BD and licensing (BDL) team will be delivering an oral presentation on Monday, June 5th at the 2023 BIO International Convention in Boston,…
Read more
Meet Biocytogen’s APAC Business Development Team at 70th JALAS 2023!
Biocytogen’s Asia-Pacific business development team is pleased to exhibit at the 70th Japanese Association for Laboratory Animal Science (JALAS) annual meeting from May 24-26, 2023…
Read more
May 2023 Newsletter
New Animal Models Humanized Immune-Checkpoint Mice Catalog Number Product 112657 B-hCD19 Mice 110888 B-hCD30 Mice 111141 B-hCD48 Mice 111257 B-hCX3CL1 Mice 112105 B-hICOS Mice 110904…
Read more
Meet Biocytogen’s Business Development Team at BIO KOREA 2023!
Biocytogen’s business development team is pleased to exhibit and host 1-on-1 meetings at BIO KOREA 2023, taking place from May 10-12, 2023 in Seoul, South Korea. Join…
Read more
Immune system-reconstituted models for immuno-oncology research: Applications of humanized B-NDG mice engrafted with CD34+ HSCs
Introduction: Choosing the right humanized model for your study The relative success of immuno-oncology drugs has directed research toward discovering novel targets and therapeutic agents.…
Read more
Webinar: Joint, Lung, and Urinary Disease Models Offered at Biocytogen
Our webinar “Joint, Lung, and Urinary Disease Models Offered at Biocytogen" was live at 1:00 PM EDT on May 25th, 2023. About the Webinar Inflammatory disease…
Read more
Humanized PCSK9 mice as a resource for lipid management studies
Introduction: mitigating dyslipidemia to prevent cardiovascular disease Dyslipidemia is a metabolic derangement that clinically presents with abnormal levels of lipids (cholesterol, triglycerides, and/or phospholipids) in…
Read more
2023 Popular Mouse Models and Cell Lines
Our advanced genome editing technologies have been leveraged by our own development scientists to create hundreds of animal and cell models used in biomedical research…
Read more
Biocytogen Announces RenLite® Licensing Agreement with Janssen
BEIJING, March 8, 2023 -- Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen") (HKEX: 02315), today announced the signing of a non-exclusive license agreement with Janssen Biotech,…
Read more
Biocytogen to Highlight Bispecific ADC Pipeline at World ADC London 2023
Biocytogen is excited to attend and deliver oral and poster presentations at the upcoming 13th World ADC London conference, held on March 13th-16th, 2023. Dr.…
Read more